January 6, 2006BMC Clinical PharmacologyOpen Access

Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat

View Full Paper

Ask AI

Bookmark

Population

Human physiologically based pharmacokinetic model applied to experimental data for ramipril and ramiprilat

Authors

DLDavid G. LevittUniversity of Minnesota RSRik C. SchoemakerHewlett-Packard (Netherlands)

Discussion

Member takes

Implication

Supports consideration of ramipril dosing intervals; extends PBPK modeling to ACE inhibitors with site-specific binding.

Structured PICO

Population

Human physiologically based pharmacokinetic (PBPK) model applied to experimental data for ramipril and ramiprilat

Intervention

Ramipril (oral and IV) and ramiprilat (IV)

Outcome

Pharmacokinetics of ramipril and ramiprilat, and time course of inhibition of N and C ACE sites in plasma and tissuessurrogate

This first human PBPK model for ACE inhibitors accurately describes ramipril pharmacokinetics and demonstrates long-lasting, non-equilibrium binding to ACE sites.

Cite This Study

Levitt et al. (2006) studied this question.

synapsesocial.com/papers/6a237d5cf11d41932608b8fb https://doi.org/10.1186/1472-6904-6-1

View Full Paper

Ask AI

Bookmark

Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider